Compare IBTA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBTA | ALLO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.3M | 738.4M |
| IPO Year | 2024 | 2018 |
| Metric | IBTA | ALLO |
|---|---|---|
| Price | $32.03 | $1.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $28.50 | $8.35 |
| AVG Volume (30 Days) | 130.5K | ★ 6.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,389,000.00 | N/A |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $8.96 | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.10 | $0.99 |
| 52 Week High | $55.63 | $4.46 |
| Indicator | IBTA | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 37.17 |
| Support Level | $21.23 | $1.85 |
| Resistance Level | $35.11 | $2.71 |
| Average True Range (ATR) | 2.08 | 0.14 |
| MACD | -0.85 | -0.02 |
| Stochastic Oscillator | 29.26 | 11.22 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).